Key pipelines include TTFields therapy combined with gemcitabine + nab-paclitaxel, which showed survival benefits in the Phase III PANOVA-3 trial (Dec 2024) https://www.datamintelligence.com/research-report/japan-locally-advanced-pancreatic-cancer-market